JPRN-UMIN000023834
已完成
未知
Impact of Dapagliflozin on Left ventricular hemodynamics and Exercise-induced Pulmonary hypertension evaluated by echocardiography in patients with type 2 diabetes; an open-label prospective randomized controlled trial - Impact of Dapagliflozin on Left ventricular hemodynamics and Exercise-induced Pulmonary hypertension evaluated by echocardiography in patients with type 2 diabetes; an open-label prospective randomized controlled trial (IDOL-EPOC Study )
The Japan Society for Patient Reported Outcome0 个研究点目标入组 78 人2016年8月30日
概览
- 阶段
- 未知
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- The Japan Society for Patient Reported Outcome
- 入组人数
- 78
- 状态
- 已完成
- 最后更新
- 2年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- 未提供
排除标准
- •Patients who fall into one or more of the following criteria are excluded from participating in the study. 1\. Patients requiring a legally acceptable representative 2\. Patients with type 1 diabetes 3\. Patients who have received an SGLT2 inhibitor, subcutaneous injection of insulin, or subcutaneous injection of glucagon\-like\-peptide\-1 agonist within 12 weeks before consenting to study participation 4\. Patients with the stage\-III hypertension (early morning systolic blood pressure measured at home is 175 mmHg or higher, or systolic blood pressure measured at office is 180 mmHg or higher) 5\. Patients with chronic respiratory disease that needs medical treatment 6\. Patients with pulmonary hypertension 7\. Patients with severe renal failure (GFR is below 45 mL/min/1\.73 m2\) 8\. Patients with an infectious disease or undergoing cancer treatment 9\. Patients who have undergone surgery or catheter treatment within a year before consenting to study participation 10\. Patients who are or may be pregnant 11\. Patients who are drug addicted or alcohol dependent 12\. Patients with NYHA III\-IV heart failure 13\. Patients considered inappropriate by their attending investigators
结局指标
主要结局
未指定
相似试验
进行中（未招募）
1 期
Impact of empagliflozin on left ventricular functionstype 2 diabetesMedDRA version: 21.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2016-002225-10-ITAZIENDA OSPEDALIERO-UNIVERSITARIA PISANA75
尚未招募
3 期
Effect of Empagliflozin on left ventricular volumes in type 2 diabetes or prediabetes patients with heart failure with reduced ejection fractioHeart failure.Heart failure, unspecifiedI50.9IRCT20211219053450N1Ahvaz University of Medical Sciences112
尚未招募
不适用
The Impact of Empagliflozin on Left Ventricular Myocardial Stiffness in Heart Failure with Preserved Ejection FractioPatients with heart failure with preserved ejecion fraction (HFpEF)Drug intervention, Empagliflozin, Pressure-Volume LoopHFpEF/I509JPRN-jRCTs071230020Hieda Michinari38
招募中
2 期
The effect of Empagliflozin on left ventricular ejection fraction in non-diabetic patients with acute anterior ST elevation Myocardial infarction treated with primary PCIAcute anterior ST elevation Myocardial infarction treated with primary PCI.ST elevation (STEMI) myocardial infarction of anterior wallI21.0IRCT20221227056950N1Mashhad University of Medical Sciences64
招募中
4 期
Effect of Dapagliflozin on LV Remodeling Post AMIMyocardial InfarctionNCT04783870Instituto Mexicano del Seguro Social60